BEIJING, Nov. 2, 2026 /PRNewswire/ — Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and AbbVie will lead global development and commercialization activities for two of Brise’s preclinical migraine programs.
"This collaboration represents an important validation of our research platform in migraine and advances our mission to deliver potentially transformative medicines to patients," said Guochun Li, Chief Executive Officer of Brise Pharmaceuticals. "By partnering with a global leader like AbbVie, we can maximize the value of our discovery engine while continuing to invest in the next wave of innovative therapies."
Under the terms of this agreement, the aggregated potential transaction value, including development, commercial, regulatory and sales milestones, could reach up to US $757 million plus royalties on future sales. As of the date of this announcement, Brise has already achieved several near-term milestones.
About Brise Pharmaceuticals
Founded in June 2021 in Shanghai, China, Brise Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering multi-modality therapeutics to transform the treatment landscape for debilitating pain conditions. The company’s mission is to develop innovative and highly differentiated treatments, with the aim to systematically improve pain management and quality of life for patients living with migraine, nociceptive, neuropathic, and nociplastic pain.
Utilizing its research and discovery engine, Brise integrates small molecules and targeted antibodies therapeutics to modulate complex pain pathways at the molecular level. The company’s pipeline currently features BR005, a novel China-originated, oral small-molecule, which is currently in pivotal clinical trials for acute treatment of migraine in adults, as well as a diverse portfolio of next-generation innovative therapeutic candidates advancing toward IND.
Learn more about the company’s therapeutic pipelines at https://www.brisepharma.com/.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
